University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

Coumarin (CAS 91-64-5)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
kid liv liv lun liv lun 39.2m,v 103m

Hamsters: Cancer Test Summary
Hamster Target Sites TD50
(mg/kg/day)
Male Female
no positive no positive no positive

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   kid = kidney. liv = liver. lun = lung. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Coumarin: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

COUMARIN (1,2-benzopyrone) 91-64-5 1562 H f syg eat 22m24 1340 0 105.mg 523.mg Ueno;fctx,19,353-355;1981 liv tum ae no dre P=1. - 222.mg n.s.s. 0/12 0/13 0/10 tba mix ae 5.52gm * P<.9 - 350.mg n.s.s. 5/12 3/13 4/10 1563 H m syg eat 24m24 1340 0 92.0mg 460.mg liv tum e no dre P=1. - 174.mg n.s.s. 0/12 0/11 0/11 tba mix e 603.mg * P<.04 - 212.mg n.s.s. 1/12 2/11 5/11 1564 M f b6c gav 24m24 TR422 : 0 35.1mg 70.4mg 141.mg liv MXA 65.7mg Z P<.003 c 35.7mg 438.mg 8/52 27/50 31/51 (13/51) liv:hpa,hpc. liv hpa 72.8mg Z P<.006 c 38.0mg 966.mg 8/52 26/50 29/51 (12/51) MXB MXB 85.5mg * P<.0005 48.1mg 302.mg 10/52 28/50 33/51 31/51 liv:hpa,hpc; lun:a/a,a/c. C lun MXA 135.mg Z P<.0005 c 87.4mg 252.mg 2/52 5/50 7/51 27/51 lun:a/a,a/c. lun a/a 179.mg Z P<.0005 c 108.mg 403.mg 2/52 5/50 7/51 20/51 lun a/c 825.mg Z P<.0005 c 355.mg 2.92gm 0/52 0/50 0/51 7/51 for sqp 12.2gm * P<1. e 417.mg n.s.s. 1/52 5/50 2/51 2/51 for MXA 42.0gm * P<1. e 376.mg n.s.s. 1/52 6/50 3/51 2/51 for:sqc,sqp. TBA MXB 198.mg * P<.2 67.2mg n.s.s. 25/52 41/50 36/51 34/51 liv MXB 65.7mg Z P<.003 35.7mg 438.mg 8/52 27/50 31/51 (13/51) liv:hpa,hpb,hpc. lun MXB 135.mg Z P<.0005 87.4mg 252.mg 2/52 5/50 7/51 27/51 lun:a/a,a/c. 1565 M m b6c gav 24m24 TR422 : 0 35.2mg 70.5mg 141.mg lun MXA 241.mg Z P<.006 p 118.mg 3.20gm 14/50 9/50 15/50 25/51 lun:a/a,a/c. lun a/a 265.mg Z P<.009 p 127.mg 7.96gm 14/50 8/50 14/50 24/51 liv hpb 632.mg Z P<.009 240.mg 16.1gm 0/50 0/50 5/50 (1/51) S for MXA 152.mg Z P<.04 e 59.2mg n.s.s. 2/50 9/50 (4/50 0/51) for:sqc,sqp. for sqp 179.mg Z P<.07 e 65.3mg n.s.s. 2/50 8/50 (2/50 0/51) --- MXA 600.mg * P<.02 301.mg n.s.s. 0/50 3/50 4/50 4/51 ---:hcs,mlh,mlm,mlp,mly. S pni isa 1.31gm * P<.03 499.mg n.s.s. 0/50 0/50 3/50 2/51 S TBA MXB 461.mg * P<.6 86.4mg n.s.s. 42/50 40/50 42/50 39/51 liv MXB no dre P=1. 137.mg n.s.s. 35/50 34/50 32/50 29/51 liv:hpa,hpb,hpc. lun MXB 241.mg Z P<.006 118.mg 3.20gm 14/50 9/50 15/50 25/51 lun:a/a,a/c. 1566 M f cd1 eat 25m25 2260 0 39.0mg 130.mg 390.mg Carlton;faat,30,145-151;1996/pers.comm. liv mix e 176.mg Z P<.002 - 79.5mg 598.mg 0/52 8/52 (4/52 3/52) lun ade e 4.50gm * P<.1 - 1.42gm n.s.s. 2/52 1/52 2/52 5/52 lun adc e 3.14gm * P<.4 - 760.mg n.s.s. 10/52 11/52 11/52 14/52 1567 M m cd1 eat 23m23 2260 0 36.0mg 120.mg 360.mg lun adc e 1.02gm * P<.04 - 417.mg n.s.s. 11/52 12/52 10/52 20/52 liv mix e no dre P=1. - 1.36gm n.s.s. 20/52 22/52 19/52 12/52 lun ade e no dre P=1. - 2.23gm n.s.s. 0/52 1/52 2/52 0/52 1568 R f f34 gav 24m24 TR422 : 0 17.6mg 35.2mg 70.3mg kid rua 1.41gm * P<.07 e 347.mg n.s.s. 0/50 0/50 0/50 2/50 TBA MXB 456.mg * P<.8 41.8mg n.s.s. 41/50 44/50 40/50 43/50 liv MXB no dre P=1. n.s.s. n.s.s. 0/50 0/50 0/50 0/50 liv:hpa,hpb,hpc. 1569 R f f34 gav 24m24 TR422 : with step 0 17.6mg 35.2mg 70.3mg kid rua 930.mg * P<.06 e 281.mg n.s.s. 0/50 0/50 1/50 2/50 1570 R m f34 gav 23m24 TR422 : 0 17.7mg 35.3mg 71.4mg tes ica as 3.62mg * P<.0005 2.33mg 6.05mg 38/50 43/50 42/51 46/50 S pit pda as 19.7mg Z P<.004 8.31mg 174.mg 19/50 12/50 16/51 (6/50) S for sqp as 142.mg * P<.04 24.5mg n.s.s. 0/50 1/50 0/51 1/50 S kid MXA as 226.mg * P<.2 p 35.2mg n.s.s. 1/50 2/50 2/51 1/50 kid:ade,rua. TBA MXB as 12.0mg * P<.0005 5.71mg 47.9mg 40/50 36/50 30/51 15/50 liv MXB as no dre P=1. 50.3mg n.s.s. 2/50 0/50 0/51 0/50 liv:hpa,hpb,hpc. 1571 R m f34 gav 23m24 TR422 : with step 0 17.7mg 35.3mg 71.4mg kid MXA as 13.9mg * P<.0005 p 6.49mg 37.1mg 1/50 6/50 7/51 5/50 kid:ade,rua. kid MXA as 13.9mg * P<.0005 p 6.49mg 37.1mg 1/50 6/50 7/51 5/50 kid:ade,rua,ruc. kid ruc as 151.mg * P<.2 24.7mg n.s.s. 0/50 1/50 0/51 0/50 1572 R m f34 gav 15m24 TR422a : 0 44.6mg tes ica 8.22mg P<.003 3.36mg 70.0mg 38/50 15/20 S kid rua 67.6mg P<.04 12.2mg n.s.s. 1/50 2/20 S TBA MXB 12.2mg P<.01 4.59mg 1.23gm 40/50 15/20 liv MXB 171.mg P<.4 19.3mg n.s.s. 2/50 1/20 liv:hpa,hpb,hpc. 1573 R m f34 gav 15m24 TR422a : with step 0 44.6mg kid rua 67.6mg P<.04 12.2mg n.s.s. 1/50 2/20 S 1574 R m f34 gav 9m24 TR422b : 0 27.1mg tes ica 19.8mg P<.3 5.48mg n.s.s. 38/50 18/20 kid rua 234.mg P<.5 27.3mg n.s.s. 1/50 1/20 TBA MXB 210.mg P<.9 9.96mg n.s.s. 40/50 14/20 liv MXB no dre P=1. 51.0mg n.s.s. 2/50 0/20 liv:hpa,hpb,hpc. 1575 R m f34 gav 9m24 TR422b : with step 0 27.1mg kid rua 43.6mg P<.01 13.6mg 11.6gm 1/50 4/20 S 1576 R f sda eat 26m26 2260 0 150.mg 250.mg Carlton;faat,30,145-151;1996/pers.comm. liv clc e 767.mg / P<.0005 + 467.mg 1.39gm 0/65 0/65 23/65 liv mix e 1.44gm / P<.0005 + 758.mg 3.41gm 0/65 1/65 12/65 1577 R m sda eat 24m24 2260 0 120.mg 200.mg liv clc e 302.mg / P<.0005 + 204.mg 475.mg 0/65 1/65 37/65 liv mix e 365.mg / P<.0005 + 234.mg 659.mg 2/65 6/65 29/65

Mutagenicity in Salmonella: positive
SMILES Code for Coumarin: O=C1OC2=C(C=CC=C2)C=C1
InChI Code for Coumarin: InChI=1/C9H6O2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-6H
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Coumarin: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10